The pharmacokinetics of darbepoetin alfa administered subcutaneously in patients with non-myeloid malignancies receiving multicycle chemotherapy.

被引：0
|
作者：
Heatherington, AC
Schuller, J
Mercer, AJ
Rovetti, RJ
Colowick, AB
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Krankenstalt Rudolfstiftung, Vienna, Austria
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1258
引用
收藏
页码：298A / 298A
页数：1
相关论文
共 50 条
  • [1] Changes in endogenous erythropoietin and the pharmacokinetics of darbepoetin alfa in patients with non-myeloid malignancies receiving or not receiving chemotherapy.
    Heatherington, AC
    Glaspy, J
    Kotasek, D
    Schuller, J
    Smith, R
    Rovetti, RJ
    Rossi, G
    [J]. BLOOD, 2001, 98 (11) : 298A - 299A
  • [2] Pharmacokinetics of Darbepoetin Alfa after Intravenous or Subcutaneous Administration in Patients with Non-myeloid Malignancies Undergoing Chemotherapy
    Anne C. Heatherington
    Christian Dittrich
    John T. Sullivan
    Greg Rossi
    Johannes Schneller
    [J]. Clinical Pharmacokinetics, 2006, 45 : 199 - 211
  • [3] Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy
    Heatherington, AC
    Dittrich, C
    Sullivan, JT
    Rossi, G
    Schueller, J
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (02) : 199 - 211
  • [4] Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy
    Esquerdo, Gaspar
    Domenech, Mercedes
    Lopez, Pilar
    Pedro, Carme
    Villadiego, Kenny
    Constenla, Manuel
    Sanchez-Rovira, Pedro
    Gasquet, Jose A.
    Rodriguez, Cesar A.
    [J]. TUMORI JOURNAL, 2014, 100 (02): : 225 - 231
  • [5] Pharmacokinetics of darbepoetin alfa: Repeated administration does not result in accumulation or altered pharmacokinetics in patients with nonmyeloid malignancies undergoing chemotherapy.
    Heatherington, AC
    Dittrich, C
    Mercer, AJ
    Rovetti, RJ
    Rossi, G
    Schueller, J
    [J]. BLOOD, 2002, 100 (11) : 173B - 174B
  • [6] Pharmacokinetics (PK) of intravenously (IV) administered epoetin alfa in pediatric patients receiving myelosuppressive chemotherapy.
    Freeman, BB
    Iacono, LC
    Hinds, PS
    Razzouk, BI
    Stewart, CF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 812S - 812S
  • [7] Darbepoetin alfa (DA) - Pattern of use and outcomes in adult patients with non-myeloid malignancies and chemotherapy-induced anemia: A French observational study.
    Pigneux, Amaud P. M.
    Ray-Coquard, Isabelle L.
    Dalivoust, Philippe J. M.
    Chenuc, Gaelle
    Bastie, Anne M.
    [J]. BLOOD, 2006, 108 (11) : 955A - 955A
  • [8] Propensity score matched evaluation of epoetin alfa and darbepoetin alfa utilization in patients with cancer receiving chemotherapy.
    Bailey, R. A.
    Tunceli, O.
    Singer, J.
    Stephenson, J. J.
    Senbetta, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Darbepoetin alfa is cost effective compared to epoetin alfa for treatment of anemia in cancer patients receiving chemotherapy.
    Glaspy, JA
    Tchekmedyian, NS
    Gupta, S
    [J]. BLOOD, 2002, 100 (11) : 874A - 875A
  • [10] The pharmacokinetics of ARANESP™ in oncology patients undergoing multicycle chemotherapy.
    Tseng, L
    Schuller, J
    Mercer, J
    Colowick, A
    [J]. BLOOD, 2000, 96 (11) : 156B - 156B
12345